تریپتورلین استات

• مکانیسم اثر تریپتورلین
  

  Triptorelin آگونیست هورمون آزاد کننده گنادوتروپین (GnRH) است و باعث مهار تولید استروئید از تخمدان ها و بیضه ها می شود به این ترتیب که سطح LH و FSH را کاهش می دهد و به دنبال آن سطح تستوسترون (در مردان) و استروژن (در زنان) کم می شود. با تجویز مزمن و مداوم تریپتورلین، معمولاً 2 تا 4 هفته پس از آغاز درمان، کاهش مداوم در ترشح FSH و LH اتفاق می افتد. در صورتی که برای ART استفاده شود، از پیک زودرس LH در زنانی که تحریک کنترل شده تخمدان در آنها انجام می شود، جلوگیری می کند.

CAS number: 140194-24-7

Sequence: Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2

Molecular formula: C₆₄H₈₂N₁₈O₁₃

Molecular weight: 1311.47 a.m.u

• مکانیسم اثر اُکتروتاید استات
  

  این ترکیب مشتق صناعی هورمون سوماتوستاتین است که 45 بار از سوماتوستاتین قوی تر است. این دارو،آزاد شدن هورمون رشد و هورمون های لوزالمعده را مهار می کند.

• فارماکوکینتیک اُکتروتاید استات

        از راه تزریقی زیر جلدی به طور کامل جذب می شود. نیمه عمر دارو حدود 5/1 ساعت می باشد.

CAS number: 79517-01-4

Sequence: Cyclo (2-7)D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Throl

Molecular formula: C₄₉H₆₆N₁₀O₁₀S₂

Molecular weight: 1019.3 a.m.u

Cas number: 881997-86-02

Sequence: Cyclo (1-7) Mpr-Har-Gly-Asp-Trp-Pro-Cys-NH2

Molecular Formula: C₃₅H₄₉N₁₁O₉S₂

Molecular weight: 831.96 a.m.u

       تتراکوزاکتاید با تحریک قشر آدرنال باعث ترشح استروئیدهای آدرنال از قبیل هیدروکورتیزون - کورتیزون - مواد آندروژنیک و مقدار کمی آلدسترون می شود.

CAS number: 60189-34-6

Sequence: H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys- Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-OH

Molecular formula: C₁₃₆H₂₁₀N₄₀O₃₁S

Molecular weight: 2933.5 a.m

CAS number: 60189-34-6

Sequence: H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys- Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-OH

Molecular formula: C₁₃₆H₂₁₀N₄₀O₃₁S

Molecular weight: 2933.5 a.m

Eptifibatide is an antiplatelet drug that reversibly binds and inhibits glycoprotein IIb/IIIa receptor of platelets. A protein found in the venom of a southeastern pygmy rattlesnake is used to make eptifibatide.

FDA approved eptifibatide for the medical management of unstable angina (UA) and non-ST elevation myocardial infarction (NSTEMI). In the PURSUIT trial, the eptifibatide showed favorable outcomes in reducing the composite end-point mortality and prevented nonfatal myocardial infarction in patients with non-ST elevation myocardial infarction and unstable angina.

Cas number: 881997-86-02

Sequence: Cyclo (1-7) Mpr-Har-Gly-Asp-Trp-Pro-Cys-NH2

Molecular Formula: C₃₅H₄₉N₁₁O₉S₂

Molecular weight: 831.96 a.m.u

• Fields of Application
  Acromegaly
  Carcinoid Syndrome
  Gastrointestinal haemorrhage

• Description
  Octreotide is a Somatostatin analogue which has increased biodisponibility due to the presence of a residue of D-Phe at the N-terminus and a residue of threoninol at the C-terminus which makes it more resistant to body enzymes. Since its discovery in 1980 it has proved to inhibit Growth Hormone and inhibit also in part glucagon and insulin. However, this peptide is quite selective in inhibiting the secretion of GH without affecting severely the levels of insulin and glucagon in blood.

Octreotide is used to treat the severe diarrhoea and other symptoms that occur with certain intestinal tumours.

It is also used to treat a condition called acromegaly, which is caused by excessive levels of growth hormone in the body. Octreotide works by reducing the amount of growth hormone that the body produces.

• Administration
  Regular injectable form and Depot injectable form.
• CAS number: 140194-24-7
• Sequence: Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2
• Molecular formula: C₆₄H₈₂N₁₈O₁₃
• Molecular weight: 1311.47 a.m.u

• Fields of Application
  Reproduction
  Prostate Cancer
  Endometriosis
  Precocious central puberty

• Description
  Triptorelin is a luteinizing hormone-releasing hormone (LHRH) agonist. The only change between LHRH and Triptorelin is the introduction of a residue of D-Triptophane instead of a glycine in position 6. The vast majority of LHRH analogue agonists show changes in this position.
• The subcutaneous and/or intramuscular injection of Triptorelin in solution or by means of depot formulations containing the peptide has shown efficacy in the treatment of ovarian carcinoma, prostatic carcinoma, endometriosis, uterine leiomyoma, fibrocystic breast disease, and precocious puberty; its use has been beneficial during in vitro fertilization protocols.

The product controls release of Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) and also levels of testoterone and estrogen. When given regularly to men, triptorelin decreases testosterone levels. Reducing the amount of testosterone in the body is one way of treating cancer of the prostate.

• Administration
  Regular injectable form and Depot injectable form.
• CAS number: 140194-24-7
• Sequence: Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2
• Molecular formula: C₆₄H₈₂N₁₈O₁₃
• Molecular weight: 1311.47 a.m.u